Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
V$438.91+2.32(+0.53%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.90+0.91(+1.14%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$759.97-35.49(-4.46%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$289.81+2.51(+0.87%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.92-1.36(-2.33%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,460.30-35.84(-2.40%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.50-8.20(-2.52%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.70+0.53(+1.15%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.84+0.98(+0.96%)Transaction in Own Shares8:00:53 AM ETIBM$256.39+2.07(+0.81%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$634.31+4.31(+0.68%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.18+1.99(+0.41%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$289.81+2.51(+0.87%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.55+5.04(+1.44%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.39+2.07(+0.81%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$196.95-3.34(-1.67%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.55+5.04(+1.44%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.65+0.43(+0.15%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.30-4.40(-2.56%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.50+1.70(+0.31%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ET

SCTX · NASDAQ

Scribe Therapeutics Inc.

$17.00 +0.21 (+1.25%)

Company overview

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$275M
Employees
89
Headquarters
Alameda, CA
Website
scribetx.com
CEO
Benjamin L. Oakes
Listed
July 24, 2026
P/E
0.00
Dividend yield
0.00%

Price chart

12.4619.5026.5533.6040.64
SCTX 1D NASDAQ O16.58H17.48L16.18C16.79+0.59 (+3.64%)Vol234.94K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
SCTXScribe Therapeutics Inc. Press release Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences GlobeNewswire
SCTXScribe Therapeutics Inc. Press release Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026 GlobeNewswire
SCTXScribe Therapeutics Inc. Stock news Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst Seeking Alpha
LQDA Stock news Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday Benzinga
SCTXScribe Therapeutics Inc. Stock news Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts Defense World
SCTXScribe Therapeutics Inc. Press release Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights GlobeNewswire
SCTXScribe Therapeutics Inc. Press release Scribe Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
See more
FAQ

Questions about Scribe Therapeutics Inc.

What does Scribe Therapeutics Inc. do?
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
What is SCTX's market cap?
Scribe Therapeutics Inc. (SCTX) is a listed stock with a live quote. The latest market cap on this page is $275M.
Where is Scribe Therapeutics Inc. headquartered?
Scribe Therapeutics Inc. is headquartered in Alameda, CA.
How do I get SCTX news from the API?
Call GET /v1/news?tickers=SCTX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does SCTX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for SCTX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the SCTX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs